Loading clinical trials...
Loading clinical trials...
A Single-arm, Single-center, Open, Prospective Phase II Clinical Study of Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
Conditions
Interventions
Camrelizumab
radiotherapy
+2 more
Locations
1
China
TianjinCIH
Tianjin, Tianjin Municipality, China
Start Date
November 1, 2020
Primary Completion Date
November 1, 2022
Completion Date
November 1, 2024
Last Updated
May 13, 2021
NCT05975593
NCT07104149
NCT05378087
NCT05950087
NCT05311566
NCT06943833
Chen
CONTACT
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions